Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{cf5e0d841a2e4237adfb01db34cea6b4,
title = "Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry",
abstract = "Locoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has been shown to improve survival. However, the effect of treatment type has not been investigated. We investigate the effect of locoregional treatment type on survival after Ltx for HCC. We investigated patients registered in the European Liver Transplant Registry database using multivariate Cox regression survival analysis. Information on locoregional therapy was registered for 4978 of 23 124 patients and was associated with improved overall survival [hazard ratio (HR) 0.84 (0.73-0.96)] and HCC-specific survival [HR 0.76 (0.59-0.98)]. Radiofrequency ablation (RFA) was the one monotherapy associated with improved overall survival [HR 0.51 (0.40-0.65)]. In addition, the combination of RFA and transarterial chemoembolization also improved survival [HR 0.74 (0.55-0.99)]. Adjusting for factors related to prognosis, disease severity, and tumor aggressiveness, RFA was highly beneficial for overall and HCC-specific survival. The effect may represent a selection of patients with favorable tumor biology; however, the treatment may be effective per se by halting tumor progression. Clinicaltrials.gov number: NCT02995096.",
keywords = "Adolescent, Adult, Aged, Carcinoma, Hepatocellular/mortality, Catheter Ablation, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Liver Neoplasms/mortality, Liver Transplantation, Male, Middle Aged, Proportional Hazards Models, Registries, Waiting Lists, Young Adult",
author = "Hans-Christian Pommergaard and Rostved, {Andreas Arendtsen} and Ren{\'e} Adam and Thygesen, {Lau Caspar} and Mauro Salizzoni and {G{\'o}mez Bravo}, {Miguel Angel} and Daniel Cherqui and {De Simone}, Paolo and Karim Boudjema and Vincenzo Mazzaferro and Olivier Soubrane and Garc{\'i}a-Valdecasas, {Juan Carlos} and {Fabregat Prous}, Joan and Pinna, {Antonio D} and John O'Grady and Vincent Karam and Christophe Duvoux and Allan Rasmussen and {European Liver and Intestine Transplant Association (ELITA)}",
note = "{\circledC} 2018 Steunstichting ESOT.",
year = "2018",
month = "5",
doi = "10.1111/tri.13123",
language = "English",
volume = "31",
pages = "531--539",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Locoregional treatments before liver transplantation for hepatocellular carcinoma

T2 - a study from the European Liver Transplant Registry

AU - Pommergaard, Hans-Christian

AU - Rostved, Andreas Arendtsen

AU - Adam, René

AU - Thygesen, Lau Caspar

AU - Salizzoni, Mauro

AU - Gómez Bravo, Miguel Angel

AU - Cherqui, Daniel

AU - De Simone, Paolo

AU - Boudjema, Karim

AU - Mazzaferro, Vincenzo

AU - Soubrane, Olivier

AU - García-Valdecasas, Juan Carlos

AU - Fabregat Prous, Joan

AU - Pinna, Antonio D

AU - O'Grady, John

AU - Karam, Vincent

AU - Duvoux, Christophe

AU - Rasmussen, Allan

AU - European Liver and Intestine Transplant Association (ELITA)

N1 - © 2018 Steunstichting ESOT.

PY - 2018/5

Y1 - 2018/5

N2 - Locoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has been shown to improve survival. However, the effect of treatment type has not been investigated. We investigate the effect of locoregional treatment type on survival after Ltx for HCC. We investigated patients registered in the European Liver Transplant Registry database using multivariate Cox regression survival analysis. Information on locoregional therapy was registered for 4978 of 23 124 patients and was associated with improved overall survival [hazard ratio (HR) 0.84 (0.73-0.96)] and HCC-specific survival [HR 0.76 (0.59-0.98)]. Radiofrequency ablation (RFA) was the one monotherapy associated with improved overall survival [HR 0.51 (0.40-0.65)]. In addition, the combination of RFA and transarterial chemoembolization also improved survival [HR 0.74 (0.55-0.99)]. Adjusting for factors related to prognosis, disease severity, and tumor aggressiveness, RFA was highly beneficial for overall and HCC-specific survival. The effect may represent a selection of patients with favorable tumor biology; however, the treatment may be effective per se by halting tumor progression. Clinicaltrials.gov number: NCT02995096.

AB - Locoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has been shown to improve survival. However, the effect of treatment type has not been investigated. We investigate the effect of locoregional treatment type on survival after Ltx for HCC. We investigated patients registered in the European Liver Transplant Registry database using multivariate Cox regression survival analysis. Information on locoregional therapy was registered for 4978 of 23 124 patients and was associated with improved overall survival [hazard ratio (HR) 0.84 (0.73-0.96)] and HCC-specific survival [HR 0.76 (0.59-0.98)]. Radiofrequency ablation (RFA) was the one monotherapy associated with improved overall survival [HR 0.51 (0.40-0.65)]. In addition, the combination of RFA and transarterial chemoembolization also improved survival [HR 0.74 (0.55-0.99)]. Adjusting for factors related to prognosis, disease severity, and tumor aggressiveness, RFA was highly beneficial for overall and HCC-specific survival. The effect may represent a selection of patients with favorable tumor biology; however, the treatment may be effective per se by halting tumor progression. Clinicaltrials.gov number: NCT02995096.

KW - Adolescent

KW - Adult

KW - Aged

KW - Carcinoma, Hepatocellular/mortality

KW - Catheter Ablation

KW - Child

KW - Child, Preschool

KW - Female

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Liver Neoplasms/mortality

KW - Liver Transplantation

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Registries

KW - Waiting Lists

KW - Young Adult

U2 - 10.1111/tri.13123

DO - 10.1111/tri.13123

M3 - Journal article

VL - 31

SP - 531

EP - 539

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 5

ER -

ID: 56535892